Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia

Area of Science:

• Biotechnology
• Immunology
• Oncology

Background:

• Therapeutic options for relapsed B cell precursor acute lymphoblastic leukemia (BPL) are limited.
• CD19 is expressed on nearly all BPL cells.
• CD19L is a natural ligand for the CD19 receptor.

Purpose of the Study:

• To investigate the potential of a novel fusion protein, CD19L-sTRAIL, as a targeted therapy for BPL.
• To assess the enhanced potency and specificity of CD19L-sTRAIL compared to sTRAIL.
• To evaluate the in vivo efficacy and safety of CD19L-sTRAIL in preclinical models.

Main Methods:

• Recombinant human CD19L-sTRAIL was constructed and characterized.
• Apoptosis induction was assessed in primary BPL cells and cell lines.
• In vivo efficacy was evaluated in xenograft models using NOD/SCID mice.
• Pharmacokinetic and toxicity profiles were determined in mice.

Main Results:

• CD19L-sTRAIL demonstrated significantly enhanced potency in inducing apoptosis compared to sTRAIL.
• The fusion protein effectively eliminated primary BPL cells and in vivo xenograft cells at low concentrations.
• CD19L-sTRAIL exhibited a favorable pharmacokinetic profile and was well-tolerated in mice at therapeutic doses.
• Potent in vivo antileukemic activity was observed in chemotherapy-resistant and relapsed BPL models.

Conclusions:

• Recombinant CD19L-sTRAIL is a potent biotherapeutic agent with potential for treating BPL.
• The targeted approach leverages CD19 expression for specific delivery and enhanced apoptosis induction.
• CD19L-sTRAIL represents a promising candidate for clinical development against BPL.